KR20180115297A - Pik3ca-관련된 과성장 스펙트럼(pros-cloves 증후군)의 치료시 사용하기 위한 byl719(알펠리시브) - Google Patents

Pik3ca-관련된 과성장 스펙트럼(pros-cloves 증후군)의 치료시 사용하기 위한 byl719(알펠리시브) Download PDF

Info

Publication number
KR20180115297A
KR20180115297A KR1020187026976A KR20187026976A KR20180115297A KR 20180115297 A KR20180115297 A KR 20180115297A KR 1020187026976 A KR1020187026976 A KR 1020187026976A KR 20187026976 A KR20187026976 A KR 20187026976A KR 20180115297 A KR20180115297 A KR 20180115297A
Authority
KR
South Korea
Prior art keywords
byl719
pros
pik3ca
syndrome
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187026976A
Other languages
English (en)
Korean (ko)
Inventor
귀욤므 꺄노
Original Assignee
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
위니베르시떼 파리 데카르트
아시스땅스 퍼블리끄-오삐또 드 빠리
상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔), 위니베르시떼 파리 데카르트, 아시스땅스 퍼블리끄-오삐또 드 빠리, 상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크 filed Critical 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
Publication of KR20180115297A publication Critical patent/KR20180115297A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Spectrometry And Color Measurement (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
KR1020187026976A 2016-02-19 2017-02-17 Pik3ca-관련된 과성장 스펙트럼(pros-cloves 증후군)의 치료시 사용하기 위한 byl719(알펠리시브) Ceased KR20180115297A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305193.1 2016-02-19
EP16305193 2016-02-19
PCT/EP2017/053587 WO2017140828A1 (en) 2016-02-19 2017-02-17 Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)

Publications (1)

Publication Number Publication Date
KR20180115297A true KR20180115297A (ko) 2018-10-22

Family

ID=55409795

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026976A Ceased KR20180115297A (ko) 2016-02-19 2017-02-17 Pik3ca-관련된 과성장 스펙트럼(pros-cloves 증후군)의 치료시 사용하기 위한 byl719(알펠리시브)

Country Status (8)

Country Link
US (4) US11433059B2 (https=)
EP (1) EP3416642A1 (https=)
JP (3) JP7051693B2 (https=)
KR (1) KR20180115297A (https=)
CN (3) CN118477076A (https=)
AU (3) AU2017219834B2 (https=)
CA (1) CA3013845C (https=)
WO (1) WO2017140828A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3294314A4 (en) * 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
AU2017219834B2 (en) 2016-02-19 2022-06-30 Assistance Publique-Hôpitaux De Paris (Aphp) BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)
KR20210124310A (ko) 2019-02-06 2021-10-14 벤테라, 인코포레이티드 국소 포스포이노시티드 3-키나제 억제제
US20240216284A1 (en) * 2021-05-03 2024-07-04 Novartis Ag Alpelisib formulation
WO2025045915A1 (en) * 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy
WO2025045129A1 (zh) * 2023-08-30 2025-03-06 广州嘉越医药科技有限公司 化合物用于治疗pros谱系疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027013A2 (en) * 2006-08-29 2008-03-06 National Cancer Centre Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
MA38522A1 (fr) * 2013-03-21 2017-10-31 Novartis Ag Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
EP3294314A4 (en) * 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
AU2017219834B2 (en) 2016-02-19 2022-06-30 Assistance Publique-Hôpitaux De Paris (Aphp) BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)

Also Published As

Publication number Publication date
CN109562103A (zh) 2019-04-02
CN118477076A (zh) 2024-08-13
US20250295645A1 (en) 2025-09-25
JP2019505549A (ja) 2019-02-28
US11433059B2 (en) 2022-09-06
EP3416642A1 (en) 2018-12-26
US20200215044A1 (en) 2020-07-09
US20220323428A1 (en) 2022-10-13
AU2017219834A1 (en) 2018-08-23
US12427141B2 (en) 2025-09-30
JP2022058800A (ja) 2022-04-12
JP7847994B2 (ja) 2026-04-20
AU2022235569B2 (en) 2024-10-10
AU2017219834B2 (en) 2022-06-30
AU2024278598A1 (en) 2025-01-16
JP2024125429A (ja) 2024-09-18
CA3013845C (en) 2024-09-17
CN118477075A (zh) 2024-08-13
US20250339417A1 (en) 2025-11-06
AU2022235569A1 (en) 2022-10-13
JP7051693B2 (ja) 2022-04-11
WO2017140828A1 (en) 2017-08-24
CA3013845A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
US12427141B2 (en) BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum (PROS-CLOVES syndrome)
CN1617715B (zh) 用雄激素受体选择性调节剂治疗肌消耗
US11723911B2 (en) Treatment of demyelinating diseases
CN108738310A (zh) 用于治疗肌营养不良的方法
EP2968238A1 (en) Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist
US10772870B2 (en) Bisamide derivative of dicarboxylic acid as an agent for stimulating tissue regeneration and recovery of diminished tissue function
JP2024521740A (ja) ２型ヨードチロニンデヨージナーゼ（ｄ２）阻害剤の新しい治療的使用
Haynie Role of sex differences on cancer cachexia progression and fibrosis during cancer cachexia development
WO2020068719A1 (en) Combined sirolimus and nintedanib therapy for vascular lesions and hereditary hemorrhagic telangiectasia
WO2004084874A2 (en) Mtp inhibitors for inhibiting inflammation
Feng et al. The role of CC motif chemokine ligand 2 in the preservation of myogenic tone in the kidney microvasculature of Dahl Salt-Sensitive rats
WO2026021460A1 (zh) 治疗前列腺癌的方法
WO2026021478A1 (zh) Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法
KR20250099240A (ko) 간질성 폐 질환 치료를 위한 n-피리디닐 아세트아미드 유도체의 경구 제형
JP2024020797A (ja) 筋萎縮の治療剤
Grujic et al. 1639: Oral Therapy with Crystalline Formulation of Oxalate Degrading Enzvme in Rodent Models with Hyperoxaluria
WO2019169113A1 (en) Compositions and methods for the treatment of endometriosis
Chen et al. 1Department of Critical Care Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, No. 136, Jingzhou Street, Xiangcheng District, Xiangyang 441021, Hubei, China. 2Department of Emergency Medicine, Xiangyang Central Hospital

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R19-X000 Request for party data change rejected

St.27 status event code: A-3-3-R10-R19-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000